It was recently reported that in contrast to advanced stage DLBCL, the cell‐of‐origin is not prognostic in limited stage disease.9, 13 To impact prognosis of these good risk patients, a biomarker, such as MYC breaks, might be helpful.12 We found an MYC translocation in 3 of 11 evaluable relapsed cases. Here, MYC is linked to diffuse large B-cell lymphoma.